December 6, 2018 / 12:14 PM / 6 months ago

Supernus Pharma's ADHD treatment succeeds in two late-stage studies

Dec 6 (Reuters) - Supernus Pharmaceuticals Inc on Thursday said its experimental treatment for attention deficit hyperactivity disorder (ADHD) met the main goal of reducing disorder symptoms in children in two late-stage studies.

The treatment, SPN-812, was being tested in children aged six to 11 years diagnosed with ADHD.

The company expects to submit a marketing application for SPN-812 in the second half of 2019, and to launch it, pending U.S. Food and Drug Administration approval, in the second half of 2020. (Reporting by Manogna Maddipatla in Bengaluru; Editing by Bernard Orr)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below